FGF21 and type 2 diabetes mellitus: While we await results from Phase 3 randomised controlled trials designed to evaluate the long‐term benefits of GLP‐1RAs on liver‐related clinical events, these findings suggest that GLP‐1RAs are a suitable treatment option (either alone or combined with other liver‐directed pharmacotherapies, such as resmetirom, peroxisome proliferator‐activated‐receptor agonists, or FGF‐21 analogues) for individuals living with MASLD or MASH, especially among those who are obese or have T2DM.